5mg/ml
Trade Name
Quillivant XR
Powder for oral suspension
Request Type
Registration
Drug Type
NCE
Approval Date
SFDA Approved Use
Methylphenidate is indicated as part of a comprehensive treatment program for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone prove insufficient.
Treatment must be initiated and supervised by a physician specialized in the treatment of ADHD such as an expert pediatrician, a child and adolescent psychiatrist or an adult psychiatrist.
Treatment must be initiated and supervised by a physician specialized in the treatment of ADHD such as an expert pediatrician, a child and adolescent psychiatrist or an adult psychiatrist.